Four-factor Prothrombin Complex Concentrate clinical trials
Also written BE1116.
How each study uses Four-factor Prothrombin Complex Concentrate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Four-factor Prothrombin Complex Concentrate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
CSL Behring (4) · Janssen Research & Development, LLC (1) · HealthPartners Institute (1) · Thomas Jefferson University (1) · University of Maryland, Baltimore (1) · University of Utah (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Four-factor Prothrombin Complex Concentrate, phase 3 first.
Studies
Open first, then newest update. How each study uses Four-factor Prothrombin Complex Concentrate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)RecruitingPhase 3CSL BehringNCT07094087Written as BE1116
- Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart TransplantationTerminatedPhase 3University of Maryland, BaltimoreNCT03341156Written as Kcentra
- Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )TerminatedPhase 3CSL BehringNCT05568888Written as BE1116
- A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04543383Written as 4-Factor Prothrombin Complex Concentrate (4F-PCC)
- Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin ReversalCompletedPhase 4HealthPartners InstituteNCT03064035Written as 4-factor prothrombin complex concentrate (4FPCC)
- FFP Versus PCC in Intracranial HemorrhageWithdrawnNot applicableUniversity of UtahNCT02429453Written as Four Factor Prothrombin Complex Concentrate
- Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate KcentraCompletedPhase 1Thomas Jefferson UniversityNCT02270918Written as Kcentra
- An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical ProcedureCompletedPhase 3CSL BehringNCT00803101Written as Beriplex® P/N (Kcentra)
- Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant TherapyCompletedPhase 3CSL BehringNCT00708435Written as Beriplex® P/N (Kcentra)
As the comparator · 1 — what is tested is compared with Four-factor Prothrombin Complex Concentrate
What changed recently
From the registry's own updates since Oct 18, 2026.